Sep. 3 at 5:49 PM
$ICU $SLS Oh, I almost forgot. The #1 BDD thus far from the FDA for the Selective Cytopheretic Device, IMHO, is for ESRD. That’s End Stage Renal Disease. Dialysis is a
$7B worldwide industry heading to
$13B in 2030- 2035. That forecast analysis omits the SCD and its AKI repairing science, however. Dialysis clinics worldwide will have dedicated SCD wings in 3-5 years prescribing regular treatments and the need for dialysis alone will be reduced by 50%+ in the next 3-7 years thanks to the SCD and SeaStar Medical Holding Corporation. You think that
$FMS $BAX and
$DVA aren’t aware of this very real possibility? It will be very revenue slashing, if they are not in a partnership, of course, in some way, in some form or fashion, with SeaStar. If you do then you best ‘Think again’!!! The handwriting, though not concretely on the wall yet is most definitely being preliminarily projected on it each and every passing day by them and every other major dialysis business everywhere!
